Skip to content
Riskpilot
← Back to search
Sign in
Get full access
LOVISENBERG UTVIKLING 3 AS
AS
Active
Org 999260497
Lovisenberggata 17, 0456
Oslo
Wholesale of pharmaceutical and medical goods
· NACE 4646
Est. 2012
20 employees
Watchlist
Share
Norway
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
LOVISENBERG UTVIKLING 3 AS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (9)
EP
Eirik Pettersen
Deputy Member
Deputy Member
2023 – 2024
MS
Marianne Stabell
Deputy Member
Deputy Member
2023 – 2024
ØR
Øyvind Rustad Hansen
Deputy Member
Deputy Member
2022 – 2023
HM
Hanne Marie Hagh Sandberg
Deputy Member
Deputy Member
2022 – 2023
GS
Geir Slotte
Deputy Member
Deputy Member
2020 – 2022
KG
Knut Grinderud
Deputy Member
Deputy Member
2022 – 2024
JE
Jan Egil Røe
Chief Executive Officer
Chief Executive Officer
2012 – 2023
SM
Solveig Marie Jølstad
Deputy Member
Deputy Member
2022 – 2024
MM
Malin Maria Davidsson
Chief Executive Officer
Chief Executive Officer
2023 – 2024
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
VH
Vidar Haukeland
Chairman
2024
MK
Martin Kravik Solheim
Board of Directors
2025
Former (8)
GJ
Gaute Jørgensen
Board of Directors
2022 – 2024
TH
Troy Hammer
Board of Directors
2022 – 2023
LR
Lars Ragnvald Vasli
Board of Directors
2020 – 2022
TB
Tord Brynjulf Haugstvedt
Deputy Chairman
2022 – 2023
LB
Lasse Bjerkås
Deputy Chairman
2023 – 2024
HK
Huong Kim Thi Nguyen
Board of Directors
2023 – 2024
EK
Erik Kreyberg Normann
Chairman
2022 – 2024
JP
Jan Petter Odden
Board of Directors
2022 – 2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Stiftelsen Diakonissehuset Lovisenberg
Company
100%
100%
2023
Stiftelsen Diakonissehuset Lovisenberg
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on LOVISENBERG UTVIKLING 3 AS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network